Successful Production and Shipment of Approximately 5 Grams of LineaDNA

Shipment Value Exceeds $390,000

Additional Multi-Gram Deliveries Expected in First Half CY2026

BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has successfully manufactured and shipped the largest single LineaDNA order in Company history, valued at over $390,000 USD.

The approximately 5-gram shipment, manufactured by the Company’s LineaRx, Inc. subsidiary, was delivered under the Company’s previously announced supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test (“the “Supply Agreement”).

"We believe this record LineaDNA shipment reflects the operational excellence and disciplined execution that define the Company," said Clay Shorrock, President and Chief Executive Officer of BNBX. "Even as we take prudent steps to right size the organization in response to market conditions, our team continues to deliver at the highest level. Fulfilling the largest single shipment of LineaDNA in our history demonstrates both the resilience of our platform and our unwavering commitment to our diagnostic and biotherapeutic partners."

The Company anticipates fulfilling additional multi-gram deliveries under the Supply Agreement in the first half of the 2026 calendar year.

About the LineaDNA™ Platform

The LineaDNA platform is a proprietary, cell-free DNA production system leveraging the Company’s deep expertise in large-scale PCR. Unlike conventional plasmid-based DNA production methods, the LineaDNA platform produces high-fidelity DNA that is free of adventitious sequences, rapidly scalable, and readily amenable to chemical modification. It can generate DNA from 100 base pairs to 20 kilobases in quantities from milligrams to grams under RUO, GLP, and GMP quality grades.

About BNB Plus Corp.

BNB Plus unlocks streamlined access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company’s differentiated strategy blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space. Formerly Applied DNA Sciences, Inc., BNB Plus continues to commercialize proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “continues,” “expect,” “objective,” “plan,” “potential,” “could,” “may,” “will,” “believe,” “project,” and other words of similar meaning. Forward-looking statements are statements other than historical facts and address various matters including, without limitation, statements relating to the anticipated ability of its LineaRx subsidiary to ship additional deliveries under one or more supply agreements, the future operating performance of the Company’s LineaRx subsidiary, and other projections or statements of plans and objectives.

These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company’s control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, failure to realize the anticipated benefits of the proposed digital asset treasury strategy; changes in business, market, financial, political and regulatory conditions, risks relating to the Company’s operations and business, including the highly volatile nature of the price of BNB and other cryptocurrencies, the illiquidity of the OBNB trust units owned by the Company, risks related to the Company’s ability to raise and deploy capital effectively, risks relating to an unproven yield generation strategy, the risk that the price of the Company’s common stock may be highly correlated to the price of the digital assets that it holds, risks related to increased competition in the industries in which the Company does and will operate, the unknown future customer demand for DNA produced by its LineaRx subsidiary, the unknown future amount of revenues and profits that will result from its LineaRx subsidiary, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally, risks relating to the treatment of crypto assets for U.S. and foreign tax purposes, risks related to the unknown returns, liquidity and/or token accumulation that the Company’s BNB treasury strategy will generate, risks relating to market volatility, cybersecurity and custody of digital assets, potential changes in laws or accounting standards relating to cryptocurrency, and regulatory developments affecting BNB or other digital assets, as well as those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

Visit www.BNB.plus for more information. Follow us on X and LinkedIn. Join our mailing list.

Web: www.BNB.plus

X: BNBX_Corp

View source version on businesswire.com: https://www.businesswire.com/news/home/20251218850366/en/